Navigation Links
Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products
Date:12/5/2008

PALM SPRINGS, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Dynamic Alert Limited (OTC Bulletin Board: DYMC) is pleased to announce that it has now identified its target markets for its pharmaceutical product line-up. The modalities will include a lozenge with some capacity for enhancing rapid onset through oromucosal absorption, topical applications, such as lotions and salves, and various products for internal use. Some products will have specific uses, while others may treat a range of problems. In keeping with both the historic medical uses of cannabis and the new scientific understanding of how cannabinoids work, Dynamic's cannabinoid pharmaceuticals will be targeting a wide-variety of serious needs such as:

    1. Neuro-muscular disorders, such as MS.
    2. Neuropathic pain, related to spinal cord injuries, as well as
       conditions such as AIDS/HIV and the side-effects of its medications,
       etc. for which opiates are not very effective.
    3. Chronic pain, to reduce or eliminate patients' dependence on opiates.
    4. Respiratory inflammation, related to both infections such as influenza
       and to autoimmune diseases such as asthma.
    5. Cancer, including pain management, control of nausea resulting from
       chemotherapy as well as loss of appetite related to the disease itself.
    6. Also control of cancer in conditions such as Pheochromocytoma.
    7. Digestive illnesses, such as gastroesophageal reflux disease (GERDS),
       Crohn's Disease and irritable bowel syndrome.
    8. Dermatological infections, such as MRSA (flesh eating disease).
    9. Sleep disorders.

President & CEO, Richard Cowan, states, "We are certainly pleased at the speed in which our business model is rolling out. The potential market size for some of these products is obviously very large. When multiplied by the various categories and compounded by multiple country rollouts, we are certainly undertaking a major pharmaceutical venture. Our success will be determined by the successes of our patients. Our strategy for success includes increasing the speed of bringing each product to market by using a multi-pronged approach. It is important to bear in mind that our ability to receive licensing fees for the various products will not have to wait on approval for use. Moreover, conventional measures of the various pharmaceutical markets do not offer a fair measure of the potential for cannabis-based medicines. For example, the huge cost of treating diseases such as MRSA is not measured by the cost of specific pharmaceuticals. Moreover, there is no simple metric for the value of reducing a patient's need for debilitating opiates. Consequently, we are extremely excited to bring such important medical advances to the people who need them most."

In each of these areas, cannabis has been proven to work, so Dynamic will have targeted formulations, which the Company plans to release via one or more of the four types of pharmaceutical product categories targeted:

    1. Possible over-the-counter Pharmaceutical Products:
       a) Non-Prescription Drugs (With disease specific claims)
       b) Nutraceuticals (No disease specific claims)

    2. Possible Prescription Pharmaceutical Medications:
       a) Psychoactive Medications
       b) Non-Psychoactive Medications

Director and Chief Science Officer, Dr. Robert Melamede, stated, "There is an enormous need for these products. Recent advances in science have opened the door to develop, produce, and commercialize a variety of effective whole plant cannabinoid-based pharmaceutical products with a wide variety of important applications. Although cannabis has been used medicinally for thousands of years, until very recently little was known about how it actually worked. Our team of scientists will develop more effective ways to produce and commercialize the production of whole plant cannabinoid-based pharmaceutical products. Even today new uses for cannabis are being found, such as the recent discovery that topical cannabis preparations can be effective against MRSA, the deadly antibiotic-resistant flesh-eating disease."

You should not place undue reliance on forward-looking statements in this press release. This press release contains forward-looking statements that involve risks and uncertainties. Words such as "will," "anticipates," "believes," "plans," "goal," "expects," "future," "intends" and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release.


'/>"/>
SOURCE Dynamic Alert Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioDynamics Provides 2007 Shareholder Meeting Update
2. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
3. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
4. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
5. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
6. Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements
7. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
8. Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules
9. U.S. Army Awards General Dynamics Contract for Biological Detection System Production and Support
10. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
11. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
Breaking Biology Technology:
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
Breaking Biology News(10 mins):